237 related articles for article (PubMed ID: 26999448)
1. Serum tryptase concentration and progression to end-stage renal disease.
Jesky MD; Stringer SJ; Fenton A; Ng KP; Yadav P; Ndumbo M; McCann K; Plant T; Dasgupta I; Harding SJ; Drayson MT; Redegeld F; Ferro CJ; Cockwell P
Eur J Clin Invest; 2016 May; 46(5):460-74. PubMed ID: 26999448
[TBL] [Abstract][Full Text] [Related]
2. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
[TBL] [Abstract][Full Text] [Related]
5. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
6. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
[TBL] [Abstract][Full Text] [Related]
8. Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
de Goeij MC; Liem M; de Jager DJ; Voormolen N; Sijpkens YW; Rotmans JI; Boeschoten EW; Dekker FW; Grootendorst DC; Halbesma N;
Nephron Clin Pract; 2012; 121(1-2):c73-82. PubMed ID: 23128440
[TBL] [Abstract][Full Text] [Related]
9. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study.
Voskamp PWM; Dekker FW; van Diepen M; Hoogeveen EK;
J Am Soc Hypertens; 2017 Oct; 11(10):635-643. PubMed ID: 28802945
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease.
Chen PM; Lai TS; Chen PY; Lai CF; Wu V; Chiang WC; Chen YM; Wu KD; Tsai TJ
J Formos Med Assoc; 2014 Apr; 113(4):219-26. PubMed ID: 24512756
[TBL] [Abstract][Full Text] [Related]
11. Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease.
Jovanovich AJ; Chonchol MB; Sobhi A; Kendrick JB; Cheung AK; Kaufman JS; Smits G; Jablonski KL;
Am J Nephrol; 2015; 42(5):361-8. PubMed ID: 26606453
[TBL] [Abstract][Full Text] [Related]
12. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
14. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
15. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
[TBL] [Abstract][Full Text] [Related]
16. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
[TBL] [Abstract][Full Text] [Related]
17. Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
Sci Rep; 2015 Nov; 5():17150. PubMed ID: 26612282
[TBL] [Abstract][Full Text] [Related]
18. Intensity of hydration changes the role of renin-angiotensin-aldosterone system blockers in contrast-induced nephropathy risk after coronary catheterisation in patients with chronic kidney disease.
Guo XS; Wu DX; Bei WJ; Li HL; Wang K; Zhou YL; Duan CY; Chen SQ; Lian D; Li LW; Liu Y; Tan N; Chen JY
J Renin Angiotensin Aldosterone Syst; 2017; 18(2):1470320317708894. PubMed ID: 28490226
[TBL] [Abstract][Full Text] [Related]
19. Mortality and Renal Replacement Therapy after Renal Artery Stent Placement for Atherosclerotic Renovascular Disease.
Misra S; Khosla A; Allred J; Harmsen WS; Textor SC; McKusick MA
J Vasc Interv Radiol; 2016 Aug; 27(8):1215-24. PubMed ID: 27296703
[TBL] [Abstract][Full Text] [Related]
20. Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study.
Roussel R; Matallah N; Bouby N; El Boustany R; Potier L; Fumeron F; Mohammedi K; Balkau B; Marre M; Bankir L; Velho G
Am J Nephrol; 2015; 42(2):107-14. PubMed ID: 26346607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
